Molina Healthcare(US:MOH) Prnewswire·2025-11-14 15:04Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by December 2, 2025 [1][3]. Company Financial Performance - Molina Healthcare reported second quarter 2025 adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [4]. - The company cut its full-year 2025 adjusted earnings per share guidance by 10.2%, revising it from at least $24.50 per share to a range of $21.50 to $22.50 per share [4]. - On July 23, 2025, Molina further reduced its full-year 2025 adjusted earnings guidance to no less than $19.00 per diluted share, representing a 13.6% cut from the previous guidance [5]. - Molina's GAAP net income for the second quarter of 2025 was reported at $4.75 per diluted share, an 8% decrease year over year, with a full-year GAAP net income guidance cut by 27% to $912 million [5]. Stock Market Reaction - Following the announcement of the second quarter results and guidance cuts, Molina's stock price fell by $6.97, or 2.9%, closing at $232.61 per share on July 7, 2025 [4]. - After the further guidance cut on July 23, 2025, Molina's stock price dropped by $32.03, or 16.84%, closing at $158.22 per share on July 24, 2025 [5]. Legal Context - The complaint against Molina alleges that the company and its executives made false or misleading statements regarding medical cost trend assumptions and the company's financial outlook [3]. - The investigation encourages investors who suffered losses to contact the firm, and it also seeks information from whistleblowers and former employees [7].